Cullinan Therapeutics Inc (NASDAQ: CGEM) is a clinical-stage oncology company advancing a diversified pipeline of targeted therapies and biologics. Its modular development model focuses on precision immuno-oncology with multiple assets in Phase 1/2 trials. Cullinan presents high-upside optionality from multiple shots on goal in cancer treatment innovation.
Últimos artículos sobre acciones